Statins in Metabolic Dysfunction-Associated Liver Disease: Hope, Hurdles, and Biostatistical Hazards.
作者信息
Kimer Nina, Tapper Elliot B
机构信息
Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.
Department of Clinical Medicine, Copenhagen University, Denmark.
出版信息
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102504. doi: 10.1016/j.jceh.2025.102504. Epub 2025 Jan 22.
Abstract
摘要
相似文献
1
Statins in Metabolic Dysfunction-Associated Liver Disease: Hope, Hurdles, and Biostatistical Hazards.他汀类药物在代谢功能障碍相关肝病中的应用：希望、障碍及生物统计学风险
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102504. doi: 10.1016/j.jceh.2025.102504. Epub 2025 Jan 22.
2
3
Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.尿酸水平与代谢功能障碍相关及代谢和酒精相关/伴发的脂肪性肝病发生的关联：一项针对接受健康检查的日本参与者的研究
Endocr J. 2025 Jun 2;72(6):671-687. doi: 10.1507/endocrj.EJ24-0622. Epub 2025 Feb 26.
4
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.他汀类药物在治疗和发展非酒精性脂肪性肝病和脂肪性肝炎中的疗效：系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101816. doi: 10.1016/j.clinre.2021.101816. Epub 2021 Oct 2.
5
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.代谢功能障碍相关脂肪性肝病：肌肉与体重的故事。
World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346.
6
Effect of Immunosuppressive Regimens on Metabolic Dysfunction-associated Fatty Liver Disease Following Liver Transplantation.免疫抑制方案对肝移植术后代谢功能障碍相关脂肪性肝病的影响。
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102387. doi: 10.1016/j.jceh.2024.102387. Epub 2024 Aug 6.
7
Extrahepatic Events in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake.代谢功能障碍相关脂肪性肝病患者的肝外事件以及遗传因素和酒精摄入的影响
Hepatol Res. 2025 Jul 1. doi: 10.1111/hepr.14233.
8
Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis.他汀类药物治疗与代谢功能障碍相关脂肪性肝炎的肝移植受者死亡率降低相关。
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102427. doi: 10.1016/j.jceh.2024.102427. Epub 2024 Oct 16.
9
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.他汀类药物用于成人心血管疾病预防：美国预防服务工作组的证据报告和系统评价
JAMA. 2016 Nov 15;316(19):2008-2024. doi: 10.1001/jama.2015.15629.
10
Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.他汀类药物对慢性肝病肝纤维化发生率、肝失代偿及死亡率的有益影响：一项系统评价与荟萃分析
Am J Gastroenterol. 2017 Oct;112(10):1495-1505. doi: 10.1038/ajg.2017.170. Epub 2017 Jun 6.
本文引用的文献
1
Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis.他汀类药物治疗与代谢功能障碍相关脂肪性肝炎的肝移植受者死亡率降低相关。
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102427. doi: 10.1016/j.jceh.2024.102427. Epub 2024 Oct 16.
2
Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver Trial.他汀类药物预防肝硬化并发症：美国对StatLiver试验的效仿。
Hepatol Commun. 2024 Sep 18;8(10). doi: 10.1097/HC9.0000000000000530. eCollection 2024 Oct 1.
3
New and emerging treatments for metabolic dysfunction-associated steatohepatitis.代谢功能障碍相关脂肪性肝炎的新疗法和新出现的疗法。
Cell Metab. 2024 May 7;36(5):912-926. doi: 10.1016/j.cmet.2024.03.011. Epub 2024 Apr 11.
4
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.代谢相关脂肪性肝病：新命名对美国肝病研究学会非酒精性脂肪性肝病实践指南的影响及更新。
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
5
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.代谢相关脂肪性肝病：一种伴有心血管和恶性并发症的全身性代谢紊乱疾病。
Gut. 2024 Mar 7;73(4):691-702. doi: 10.1136/gutjnl-2023-330595.
6
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial.阿托伐他汀治疗肝硬化患者：一项随机、安慰剂对照试验。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000332.
7
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.代谢相关脂肪性肝病与心血管疾病风险。
Gut. 2024 Feb 23;73(3):533-540. doi: 10.1136/gutjnl-2023-331003.
8
Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease.他汀类药物与非肝硬化慢性肝病患者严重肝病风险降低相关。
Clin Gastroenterol Hepatol. 2024 Apr;22(4):749-759.e19. doi: 10.1016/j.cgh.2023.04.017. Epub 2023 Apr 28.
9
Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials.他汀类药物和阿司匹林对酒精性肝硬化相关 HCC 风险的影响：全国模拟试验。
Hepatol Commun. 2023 Jan 3;7(1):e0013. doi: 10.1097/HC9.0000000000000013. eCollection 2023 Jan 1.
10
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.代谢风险因素与非酒精性脂肪性肝病（NAFLD）患者发生进展性肝疾病的关系：基于人群的观察性研究的系统评价和荟萃分析。
PLoS Med. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100. eCollection 2020 Apr.
Zotero 插件